Low Red Blood Cell Count And Parkinson’s

Estimating Blood Cell Counts Based On Dna Methylation Levels

We estimate blood cell proportions using two different software tools. Houseman’s estimation method , which is based on DNA methylation signatures from purified leukocyte samples, was used to estimate the proportions of CD8+ T cells, CD4+ T, natural killer, B cells, and granulocytes. Granulocytes are also known as polymorphonuclear leukocytes. The advanced analysis option of the epigenetic clock software was used to estimate the percentage of exhausted CD8+ T cells and the number of naïve CD8+ T cells .

Cancer And Parkinsons Disease

Several epidemiological studies have reported an association between cancer and PD, supporting generally a decreased risk of PD among almost all cancer types. A meta-analysis of 29 studies found that a diagnosis of PD was associated with an overall 27% decreased risk of cancer, and 38% decreased risk after excluding melanoma and other skin tumors . Consistently, another meta-analysis of 50 observational studies reported a 17% decreased risk of cancer in PD patients . Cancers of the prostate, lung, bladder, colorectal, blood and uterus were among the most reduced in PD patients . A detailed review of associations between PD and cancer has been published elsewhere .

While most of the studies suggest an overall negative association between PD and cancer, some studies have indicated the opposite. For example, several studies have reported that PD patients are at higher risk of developing brain tumors and breast cancer in women . Additionally, PD patients harboring a G2019S LRRK2 mutation have been shown to have higher cancer rates than non-mutation carriers, especially for hormonal-related cancers and breast cancer in women . Conversely, some studies have not found a significant association between breast cancer and PD .

Pathway Enrichment Analysis Indicates Changes In Mch May Have An Impact On Haematological Gene Expression

As the AddNeuroMed cohort also contained whole blood whole genome transcript data, we were able to use this dataset to explore, using several approaches, the gene expression patterns and hence KEGG pathways, linked to both blood traits and to AD. Initially, we used all subjects with both expression and rate of change in MCH data in a fold change analysis to look for significantly associated genes , finding an enrichment for the glycosylphosphatidylinositol anchor biosynthesis pathway in those with greatest rate of change in MCH. Defects in this pathway cause paroxysmal nocturnal haemoglobinuria, a genetic disorder whereby the immune system destroys red blood cells. We then focussed in on the AD group with complete data as above to look for correlation between rate of decline in blood indices and gene expression. Using this filtered approach, we detected an enrichment for haematopoietic cell linage pathway correlating with MCH rate of decline . In both cases, we found weaker p values at the initial analysis stage, which is to be expected given the sample size.

Don’t Miss: How Long Does A Parkinson’s Patient Live

Causes For A Low Red Blood Cell Count

Iron deficiency anemia: The most common cause of low red blood cells is anemia due to iron deficiency. This can be caused by losing a lot of blood, a decrease in iron absorption from food by the body, reduced iron intake via your diet, malnutrition, etc. Pregnancy can lead to anemia due to the increase in demand for iron supply to the fetus.

Other types of anemia: A low red cell count could arise from other types of anemia, such as chronic diseases , autoimmune hemolytic anemia, and aplastic anemia.

Hemolysis: The breakdown or destruction of red blood cells is called hemolysis. Hemolysis can be caused by an autoimmune reaction to a blood transfusion, infection, or genetic diseases, such as sickle cell anemia.

Treatments: In cancer patients, chemotherapy or radiation therapy can cause mass destruction of red blood cells. The process involves strong chemicals and radiations that can be harmful to blood cells, thereby diminishing them.

Heavy menstruation: People who experience heavy period flow regularly may tend to have a low red blood cell count. If they do not compensate for the loss adequately through their diet, their blood count is reduced and does not get replenished, leading to a low red blood cell count.

Blood Transfusions To Treat Anemia

A blood cell transfusion is a safe and a common way to treat anemia in people with cancer. It can help the patient feel better and helps oxygen get to vital organs. While blood transfusions can help symptoms very quickly, sometimes the relief is temporary depending on the cause of anemia.

Whether a blood transfusion might be needed depends on how severe your symptoms are and your hemoglobin level. A transfusion might be done if your hemoglobin level reaches a certain number or if your symptoms get too bothersome

A blood transfusion requires careful matching of donated blood to the recipients blood. Blood products are tested to be sure they are safe and the same kind of blood type as the recipient. But, receiving a blood transfusion also has some risks

Also Check: Is There Any Cure For Parkinson’s Disease

What Is The Treatment For Low Red Blood Cells

Treatment for low red blood cells depends on the type of anemia.

For low red blood cells caused by iron deficiency anemia, the first step is to determine the cause of the low iron. If low iron is due to blood loss, such as from stomach ulcers or bowel problems, those issues need to be treated

People with iron deficiency anemia need additional iron. Eating foods high in iron is not sufficient. Iron supplementation may be given:

• Orally as pills or liquid

Given to people who cannot absorb an adequate amount of iron from pills

If iron deficiency anemia is severe, a blood transfusion may be needed.

For some cases of anemia of inflammation, erythropoietin or erythropoiesis-stimulating agents that help the body produce more red blood cells may be used.

Autoimmune hemolytic anemia is treated with:

• Treating the underlying condition such as lupus or CLL
• Cyclophosphamide or rituximab if prednisone does not work well

Blood transfusions

Removal of the spleen

Treatment for aplastic anemia depends on the cause and may include:

• Stopping medicines that caused the problem
• Never stop taking a prescribed medication without first talking to your doctor

Avoiding toxic chemicals

Biological And Clinical Implications Of Comorbidities In Parkinsons Disease

• Department of Cellular and Molecular Pharmacology, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States

A wide spectrum of comorbidities has been associated with Parkinsons disease , a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.

You May Like: Craft Activities For Parkinson’s Patients

Anemia And Red Blood Cell Count

Are you feeling weak or fatigued? You may be experiencing symptoms of anemia. Anemia occurs when your red blood cell count is low. If your RBC count is low, your body has to work harder to deliver oxygen throughout your body.

RBCs are the most common cells in human blood. The body produces millions each day. RBCs are produced in the bone marrow and circulate around the body for about 120 days. Then, they go to the liver and spleen, which destroy them and recycle their cellular components.

Anemia can put you at risk of a number of complications, so its important to see a doctor or healthcare professional if youre experiencing symptoms. If youre diagnosed with anemia, a doctor will provide a treatment plan to help you get your RBC levels back on track as soon as possible.

Keep reading to learn how to increase your RBCs at home, how a doctor can help, and more.

Changes In Blood Pressure Cholesterol Levels May Predate Motor Symptoms In Parkinson Disease

Changes in blood pressure, percentage of red blood cells, and serum cholesterol levels were found to occur in patients with Parkinson disease before the onset of motor symptoms, suggesting potential biomarkers for early diagnosis and treatment.

Changes in blood pressure, percentage of red blood cells, and serum cholesterol levels were found to occur in patients with Parkinson disease before the onset of motor symptoms, according to study findings published in Scientific Reports.

PD, the second most common neurodegenerative disorder after Alzheimer disease, is a commonly misdiagnosed condition. In fact, a prior survey found that 21% of patients with PD had to see their general provider 3 times before being referred to a specialist.

As the studys accompanying press release notes, more than half of all dopaminergic neurons are already lost in PwP when motor symptoms like tremor and stiffness begin. Recent attempts to identify diagnostic biomarkers have indicated that some nonmotor symptoms, such as constipation and vision and eye issues, may predate the onset of motor symptoms in PD.

“If we can detect biological changes in the patients’ bodies well before the onset of the motor symptoms, we can start medical treatments in an early stage,” said Masahisa Katsuno, MD, professor in the Department of Neurology at the Nagoya University Graduate School of Medicine, in a statement.

Reference

Don’t Miss: What Is Early Onset Parkinson’s

Bone Symptoms Of Gaucher Disease

Bone problems are common in people with Gaucher disease. With early treatment, you can minimize any permanent harm to your bones and joints.

Gaucher disease symptoms affecting the bones include:

• Bone pain and bone crisis: Patients often experience bone pain, including severe episodes called bone crisis resulting from reduced blood flow to the bones.
• Bone infarction or avascular necrosis : This condition occurs when parts of the bone dont get enough oxygen, causing bone tissue to deteriorate and die. Bone infarction often leads to hip or shoulder problems, severe arthritis and increased fracture risk.
• Osteopenia and osteoporosis: Gaucher disease causes loss of calcium and mineral content in the bones in male and female patients of all ages. Smoking, excessive alcohol use, lack of physical activity and certain medications can add to the risk of osteoporosis in patients with Gaucher disease.
• Spontaneous fractures: Osteopenia and osteoporosis weaken the bones, making them more likely to break. Bone fractures in patients with Gaucher disease can occur even without trauma.
• Joint pain, arthritis and joint damage: It is common for patients with Gaucher disease to experience joint pain. Gaucher disease can cause severe arthritis and joint damage, which can be permanent if the disease is untreated.

Increased Epigenetic Age And Granulocyte Counts In The Blood Of Parkinson’s Disease Patients

Steve Horvath1,2,, Beate R Ritz3,4,5,,

• 1 Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
• 2 Department of Biostatistics, UCLA Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
• 3 Department of Neurology, UCLA School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA
• 4 Department of Epidemiology, UCLA Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA
• 5 Department of Environmental Health, UCLA Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA 90095, USA

Received: September 23, 2015 Accepted: November 30, 2015 Published: December 9, 2015

You May Like: Do Parkinson’s Patients Get Violent

Harvard Biomarker Study: Snca Mrna Abundance In Early

We first evaluated relative SNCA mRNA abundance in a case-control study nested in the HBS using precise, kinetic, quantitative PCR based on fluorogenic 5 nuclease chemistry . We specifically designed the HBS as a clinical biomarker study with rigorous, predefined collection and processing protocols. Cases and controls had similar ages, but patients with Parkinsons disease were more likely to be males . Cases were at an early stage of the disease, with a mean modified Hoehn and Yahr stage of 2.1. A large majority of cases were on medications that ameliorate the dopamine deficiency caused by the degeneration of neurons in the substantia nigra, while 9.5% were untreated, de novo patients. The controls were recruited from the same source population. Case and control samples were collected, processed, and analysed in parallel. Samples were required to meet stringent quality control criteria in order to enter the study including a RNA Integrity Number threshold of 7.3 indicating high RNA quality. The two groups had excellent RNA quality with mean RINs of 8 ± 0.4 versus 8.05 ± 0.4 , respectively.

General linear model analysis was performed adjusting for the covariates of counts of white and red blood cells, and gender. In this covariate-adjusted analysis the mean relative abundance of SNCA expression was 17% lower in cases than in controls with P = 0.003.

.

Anemia Increases Pd Risk

Within a mean follow-up period of 6.6 years, newly diagnosed anemic patients were at a higher risk of PD than nonanemic controls were, after exclusion of patients who developed PD within 3 years of enrolment. The exclusion was made to prevent biases caused by simultaneous diagnosis of anemia and PD and by PD unmasked by anemia. The incidence rates of PD in the anemic patients and nonanemic controls were 2.38 and 1.69 per 1,000 person-years, respectively, with an adjusted hazard ratio of 1.36 for the anemic patients , based on the competing risk regression model. The aHRs for developing PD in the patients with and without iron deficiency anemia were 1.49 and 1.29 , respectively . The results obtained from competing risk models for stratified data showed similar significantly increased risk .

Figure 2

Cumulative hazards of PD based on competing risk regression analyses.

The aHR of developing PD was 1.36 for anemic patients. The aHRs of developing PD for patients with and without iron IDA were 1.49 and 1.29 , respectively.

Iron supplementation to IDA patients did not significantly affect PD risk . The aHR of developing PD in IDA patients without iron supplementation was 1.86 and that in IDA patients with more than 28 days of iron supplementation was 1.32 . Similar results were obtained from competing risk models for stratified data .

Figure 3

Cumulative hazards of PD for patients with IDA based on competing risk regression analyses.

Don’t Miss: 5 Signs You Ll Get Parkinson’s

Patient Selection And Demographic Data

The detailed process of patient selection is presented in . shows the demographics and disease conditions of newly diagnosed anemic patients and nonanemic control patients. Of all the anemic patients , 75.9% were women and the mean age was 56.4±11.5 year-old. The prevalence of previous or current comorbidity among the anemic patients was 30.1%, 15.5%, 20.8% and 5.1% for hypertension, diabetes, hyperlipidemia and gout, respectively. Ibuprofen was prescribed for 25.1% of the anemic patients. After propensity score matching , the anemic patients and nonanemic controls exhibited nonsignificant differences in all the covariates.

Table 1 Baseline characteristics of anemic patients and propensity score-matched controls.

Tests For Causes Of Anemia

A complete blood count is a blood test that measures your hemoglobin level and other characteristics of your red blood cells . This test not only shows if you have anemia, but it can also help your doctor figure out what might be causing it.

You might also need other tests to help to find what is causing it. These could include:

• Blood chemistry tests to check organ function and levels of vitamins and minerals
• A blood test called a reticulocytecount
• A bone marrow exam to make sure your bone marrow is working as it should
• Blood tests to look at your iron, vitamin B12, and folate levels
• A test of your stool to check for blood

Your doctor or nurse can use the results of these tests, along with your medical information and a physical exam, to get an idea of what might be causing your anemia. Sometimes no cause can be found other than anemia of chronic disease. This type of anemia is often found in people with long-lasting problems like congestive heart failure, inflammatory diseases, or cancer.

Recommended Reading: Parkinson’s Foundation Of Michigan

What Are Low Red Blood Cells

Red blood cells carry oxygen in the blood. When a person has low red blood cells , the body may not be getting the oxygen it needs.

What Are Symptoms of Low Red Blood Cells ?

Many people with low red blood cells have no symptoms. When symptoms occur, they may include:

• Chest pain or trouble breathing
• Abnormal cravings for non-food items, such as clay or dirt, paper products, or cornstarch
• Abnormal craving to eat ice
• Pale skin or a pale color in the tissue that lines the inside of the eyelids
• Reddish or brown urine
• More frequent infections
• More bruising or bleeding than normal

Parkinsons Disease: Beyond Motor Symptoms

Parkinsons disease is an incurable neurodegenerative disease affecting 710 million people worldwide1. PD is clinically categorized as a movement disorder with prominent motor symptoms, which include tremors, rigidity and bradykinesia . Motor symptoms usually appear late in the disease process as a result of dopaminergic cell death and accumulation of alpha synuclein , a major constituent of Lewy bodies and a pathological hallmark of PD . Current therapies for PD confer symptomatic relief but to date, there is no treatment available to halt or slow the progression of the disease. The lack of fully validated biomarkers to detect patients in the early stages of the disease continues to be a major limitation in the design and outcome of clinical trials testing potential drugs and/or neuroprotective agents.

Figure 1. Non-motor conditions and comorbidities associated with Parkinsons disease . Non-motor conditions and comorbidities have a detrimental impact in the quality of life and clinical status of PD patients. Some of these conditions may precede the onset of PD. Drugs to treat type 2 diabetes, depression, anemia and cancer are currently being tested in clinical trials for PD .

You May Like: Parkinson’s Side Effects Elderly